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Abstract
Pyridine is a unique aromatic ring. Although pyridines are used industrially, pyridine 
moieties are present in many natural products, such as vitamins, coenzymes, and alka-
loids, and also in many drugs and pesticides. Pyridine moieties are often used in drugs 
because of their characteristics such as basicity, water solubility, stability, and hydrogen 
bond-forming ability, and their small molecular size. Because pyridine rings are able to 
act as the bioisosteres of amines, amides, heterocyclic rings containing nitrogen atoms, 
and benzene rings, their replacement by pyridine moieties is important in drug discov-
ery. Recently, we synthesized a series of BACE1 inhibitors by in silico conformational 
structure-based drug design and found an important role of pyridine moiety as a scaf-
fold. In this chapter, we describe the important role of pyridines in medicinal chemistry 
and the development of β-secretase inhibitors possessing a pyridine scaffold for the treat-
ment of Alzheimer’s disease.
Keywords: Alzheimer’s disease, BACE1 inhibitor, bioisostere, drug design, in silico 
conformational structure-based design
1. Introduction
Alzheimer’s disease (AD) is the most common cause of dementia. AD is characterized by pro-
gressive intellectual deterioration. In 1906, Alois Alzheimer, a psychiatrist and a neuropathol-
ogist, reported on a 51-year-old female at the Frankfurt Asylum. The patient showed strange 
behavioral symptoms and loss of short-term memory, which was later called “AD.” The cause 
of AD has only been clarified relatively recently, and there have been no therapeutic agents 
since that first report by Dr. Alzheimer over 100 years ago. Recently, the development of 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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many drug candidates based on the amyloid hypothesis has been reported. β-Secretase 
(BACE1; β-site amyloid precursor protein-cleaving enzyme 1) is a promising molecular 
target for the development of anti-Alzheimer’s drugs. BACE1 triggers the formation of the 
amyloid β (Aβ) peptide that is the main component of the senile plaques found in the brain 
of AD patients. We designed a series of peptidomimetic inhibitors possessing a substrate 
transition-state analog. We followed this with the design of nonpeptidic BACE1 inhibitors 
possessing a pyridine scaffold, using an approach based on a conformer of the docked 
ligand in the target biomolecule—the “in-silico conformational structure-based design.” In 
this process, we noticed an important and third role of pyridines in medicinal chemistry. 
Pyridines are contained in many natural products, such as vitamins, coenzymes, and alka-
loids. Pyridine moieties are often used in drugs and pesticides because of characteristics 
that include basicity, water solubility, stability, hydrogen bond-forming ability, and small 
molecular size. In this chapter, the conventional roles of pyridine in medicinal chemistry 
are described. We also introduce another role using our example regarding the design of 
BACE1 inhibitors.
2. Conventional roles of pyridine in medicinal chemistry
Pyridine rings are present in many natural products including vitamins such as niacins and 
vitamin B
6
, coenzymes such as nicotinamide adenine dinucleotide (NAD), and alkaloids 
such as trigonelline. Trigonelline is an alkaloid that is the product of niacin metabolism. 
Many drugs and pesticides contain a pyridine moiety. Examples include antimicrobial 
agents, antiviral agents, antioxidants, antidiabetic agents, anti-malarial agents, anti-inflam-
matory agents, psychopharmacological antagonists, and antiamoebic agents [1]. These 
pyridine moieties play critical roles in medicinal chemistry because of their abovemen-
tioned characteristics. One role of pyridine in medicinal chemistry is to improve water 
solubility because of its weak basicity. Although many drugs and pesticides possessing a 
pyridine ring had been designed for improved water solubility, this improvement is often 
pH-dependent. For example, the sulfa drug, sulfapyridine 1 (Figure 1A) has good antibac-
terial activity and water solubility under acidic conditions, but there is a risk of crystalliza-
tion in the bladder or urethra, which leads to pain or blockage of the urethra. The conjugate 
of sulfapyridine and 5-aminosalicylic acid by an azo bond is the compound called sul-
fasalazine 2 (Figure 1A). It displays good water solubility and is used in clinical practice 
in the treatment of rheumatoid arthritis, ulcerative colitis, and Crohn’s disease [2]. When 
the parent compound cannot be substituted with a pyridine ring, there is an alternative 
solution—water-soluble prodrug. Water-soluble prodrug 3b (isavuconazonium sulfate) of 
an antifungal agents is shown in Figure 1B [3]. Prodrug 3b hydrolyzed by an esterase to 
release an intermediate 4b. Prodrug 4b can spontaneously release the parent drug, isavu-
conazole 5, in physiological conditions. Prodrug 3b, which possesses a pyridine ring, dis-
plays good water solubility (>100 mg/mL) compared to prodrug 3a (>10 mg/mL) that lacks 
pyridine ring. Prodrug 3b was approved as an oral medicine by the United States Food and 
Drug Administration (FDA) in 2015.
Pyridine10
Bioisosteres have an important role in the pyridine ring for medicinal chemistry [4]. 
Bioisosteres are functional or atomic groups with similar physiochemical properties to the 
parent functional/atomic groups.
Compounds associated with them exhibit similar biological or physiochemical properties as 
the parent compound. In medicinal chemistry, a portion of a candidate drug is replaced with 
other functional/atomic groups with the goal of improving drug efficacy, in vivo stability, 
oral absorption, membrane permeability, and absorption, distribution, metabolism and excre-
tion (ADME). Among the approaches used for drug discovery research, the modification of 
drug candidates by their corresponding bioisosteres is the first choice in drug design studies. 
Because pyridine is a unique aromatic ring that features a small molecular size, weak basicity, 
and good stability, pyridine rings had been used as the bioisostere for other heterocyclic aro-
matic rings, benzene rings, amides, and amines [4]. Especially, pyridines are often replaced 
with monocyclic aromatic rings, such as benzenes, imidazoles, pyrrole, and oxazole rings, 
Figure 1. (A) Drugs with improved water solubility. (B) Isavuconazonium sulfate, a water-soluble prodrug possessing 
a pyridine ring.
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because of their same molecular size as the pyridine ring. Some drugs with a pyridine ring 
as a bioisostere of imidazole and benzene ring are presented in Figure 2. Histamine has an 
amino group and an imidazole ring. Thus, histamine receptor antagonists with the respec-
tive bioisosteres of the amino group and an imidazole ring have been designed. Cimetidine 6 
(Figure 2A) is an H
2
 receptor antagonist, which has an imidazole ring and a guanidine deriva-
tive as the analog of an amino group [5]. The H
2
 receptor belongs to the rhodopsin-like fam-
ily of G protein-coupled receptors. Because the H
2
 receptor stimulates gastric acid secretion, 
its antagonists such as cimetidine are used in the treatment of heartburn and peptic ulcers. 
Mepyramine 7 (Figure 2A) has a pyridine ring as a bioisostere of the imidazole ring. The com-
pound has histamine H
1
 receptor antagonist activity [5]. Histamine receptor H
1
 is expressed in 
smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. 
H
1
 receptor antagonists are used as antiallergy drugs. Some histamine antagonists in which 
imidazole ring of the ligand is replaced with a bulky aromatic ring such as doxepin [6] display 
H
1
 receptor antagonist activity, indicating that this ligand site appears to decide the affinity 
toward the histamine receptor subtypes.
Figure 2. (A) Histamine and histamine receptor antagonists and (B) matrix metalloproteinase (MMP) inhibitors.
Pyridine12
Matrix metalloproteinases (MMPs) are calcium- and zinc-containing endopeptidases that 
have diverse roles in cell behaviors including cell proliferation, migration, and differentia-
tion. Some MMP family subtypes, which include MMP2, MMP3, and MMP9, can degrade 
the extracellular matrix, resulting in the accelerated infiltration and migration of cancer cells. 
Inhibitors of some MMP subtypes had been reported for anticancer activity. Most MMP 
inhibitors have a hydroxamic acid that can bind to the zinc-containing sites of MMPs [7]. The 
second-generation MMP inhibitors such as batimastat 8 have a more potent inhibitory activ-
ity than that of the first-generation MMP inhibitors such as marimastat 9. (Figure 2B), but 
their selectivity against MMP subtypes is insufficient. The third-generation MMP inhibitor 
prinomastat 10 has a pyridine ring at the P
1
’ position, which improves the selectivity to MMP2 
and MMP9. A deep hydrophobic pocket corresponding to the S
1
’ sites is located near the zinc-
binding site of MMP, and an alkyl or phenyl groups of amino acids of inhibitors can bind to 
the S
1
’ pocket. Researchers at Shionogi & Company Limited reported that the biphenyl group 
of a third-generation MMP inhibitor, BPHA, can interact tightly with the deep S
1
’ pocket 
[8]. The pyridine ring of prinomastat appears to behave as a bioisostere of the benzene ring. 
As stated earlier, pyridines had been used in medicinal chemistry because of their unique 
properties, such as weak basicity, water solubility, in vivo/chemical stability, hydrogen bond-
forming ability, or small molecular size.
3. Design of BACE1 inhibitors
3.1. Pathology of AD and design of peptidomimetic inhibitors
AD is the most common cause of dementia. Its cause has been unclear. A breakthrough was 
made through the genetic study of some familial AD (FAD) patients with a mutation of the 
gene encoding amyloid precursor protein (APP) or presenilin gene. As these mutations caused 
an increase in Aβs that are the main components of senile plaques in the brain of patients with 
AD, it indicates their involvement in the pathogenesis of AD [9–12]. Aβs are produced from 
APP by two processing enzymes, β-secretase (BACE1; β-site APP-cleaving enzyme 1) and 
γ-secretase, which are potential molecular targets for anti-AD drugs [13–16]. The cleavage 
sites of APP are shown in Figure 3A. The full-length APP (APP770) and its isoforms, APP695 
and APP751, result from the alternative splicing of its mRNA. BACE1 is a type I transmem-
brane aspartic protease with 501 amino acids, which triggers Aβ formation in the rate-limiting 
first step by cleaving at the N-terminus (β-site) of the Aβ domain of APP. Next, the aspartic 
protease, γ-secretase, cleaves at the C-terminus of the Aβ domain, releasing Aβs that con-
sists mainly of two molecular species, Aβ
1–42
 and Aβ
1–40
. γ-Secretase cleaves two cleavage sites 
“γ-sites” forming Aβ
1–40
 and Aβ
1–42
. Two processing enzymes, BACE1 and γ-secretase, are cat-
egorized as aspartic proteases. They have an acidic optimum pH. Furthermore, BACE1 and 
γ-secretase, and their substrate, APP, are located in the same intracellular granules, such as 
endosomes and the trans-Golgi network, which have an acidic environment, suggesting that 
Aβs are produced in these locations [17]. Aβ
1–42
 displays more potent neurotoxicity and aggre-
gation behavior than Aβ
1–40
 and appears to be critical in the pathogenesis of AD. By contrast, 
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α-secretase is a disintegrin and metalloprotease (ADAM) family metalloprotease, for example, 
ADAM9, ADAM10, and TNF-α-converting enzyme (TACE, also known as ADAM17), which 
cleaves APP at the α-site between Lys16 and Leu17 in the Aβ domain [17]. A homolog enzyme 
of BACE1, BACE2, cleaves at two sites (θ-sites) between Phe19 and Phe20, and between Phe20 
and Ala21 in the Aβ domain [18]. Because the α-site and θ-sites are located at the center of the 
Aβ domain, their cleavage does not lead to Aβ production. According to the amyloid hypoth-
esis, BACE1 and γ-secretase are the molecular targets for anti-AD drugs. However, because 
γ-secretase can cleave other single-pass transmembrane proteins in vivo such as Notch, which 
plays a critical role in cell differentiation, its inhibition appears to lead to serious side effects. 
The fact that BACE1 knockout transgenic mice can survive normally has provided a promis-
ing road map, in which BACE1 is a molecular target for the development of AD drugs [19].
As BACE1 is an aspartic protease, early BACE1 inhibitors are peptidomimetic with a substrate 
transition-state analog. They were designed on the basis of an inhibitor design approach as 
well as other aspartic proteases such as renin and human immunodeficiency virus protease 
[20–26]. Many mutations in the APP gene that affect Aβ formation, Aβ
1–42
/Aβ
1–40
 ratio or Aβ 
toxicity have been reported. Among them, the Swedish mutation (K670 N, M671 L double 
mutation, Figure 3A) around the β-site induces β-cleavage by BACE1, increasing the Aβ
1–42
 
and Aβ
1–40
 levels in the brains of AD patients. Because the Swedish-mutant APP is cleaved 
faster than the wild-type APP, early BACE1 inhibitors were designed on the basis of the 
Figure 3. (A) Amyloid precursor protein (APP) and its cleavage site and (B) peptidomimetic BACE1 inhibitors designed 
on the basis of Swedish-mutant APP sequence by Ghosh et al.
Pyridine14
Swedish-mutant APP amino acid sequence. In 1999, Sinha et al. at Elan Pharmaceuticals suc-
ceeded in purifying BACE1 from the human brain using a transition-state analog based on the 
Swedish-mutant sequence and cloned the BACE1 enzyme [16]. In 2000 and 2001, Ghosh and 
Tang described the potent inhibitors, compounds 11 (OM99–2, Ki = 1.6 nM) and 12 (OM00–3, 
Ki = 0.3 nM) with a transition-state analog corresponding to a dipeptide unit at the P
1
–P
1
’ posi-
tions of APP (Figure 3B) and provided the first X-ray crystal structure (PDB ID: 1FKN) of a 
complex between recombinant BACE1 and the inhibitor OM99–2 [27–30].
We have also reported a series of peptidomimetic BACE1 inhibitors possessing a norsta-
tine-type transition-state analog, phenyl norstatine (Pns: (2R,3S)-3-amino-2-hydroxy-4-
phenylbutyric acid), at the P
1
 position as shown in Figure 4 [31–38]. These inhibitors have 
a Glu bioisostere at the P
4
 position and a C-terminus anilide substituted by an acidic group 
corresponding to the Asp residue at the P
1
’ position of the APP sequence. Among the com-
pounds, 13 (KMI-429, IC
50
 = 3.9 nM) effectively inhibits BACE1 activity in cultured cells and 
significantly reduces Aβ production in vivo when directly administered into the hippocampi 
of APP transgenic and wild-type mice [31, 32]. The most potent inhibitor, compound 14 (KMI-
684, IC
50
 = 1.2 nM) features two carboxylic acid residues of KMI-429 at the P
1
’ position that 
have been replaced with their bioisostere, a tetrazolyl ring [33]. Compound 15 (KMI-574, 
IC
50
 = 5.6 nM), which possesses a 5-fluoroortyl group in the N-terminus residue, displays 
improved inhibition in cultured cells because of improved cell membrane permeability [34].
3.2. Design of nonpeptidic BACE1 inhibitors with a pyridine scaffold
We designed and synthesized nonpeptidic BACE1 inhibitors from our peptidic BACE1 inhibi-
tors 13–15 as lead compounds [20–25]. Researchers at MSD, Elan, and Pfizer, and Gosh et al. 
reported a series of BACE1 inhibitors possessing an isophthalic scaffold at the P
2
 position [23, 25]. 
Figure 4. Peptidomimetic BACE1 inhibitor with a norstatine-type substrate transition-state analog.
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The inhibitors formulated by Elan and MSD researchers, compounds 16 and 17, respectively, 
are shown in Figure 5. Because the distance between the flap domain and the cleft domain 
that form the S
2
 pocket of BACE1 is narrow, a planar aromatic ring such as an isophthalic 
scaffold can closely dock in the S
2
 pocket of BACE1. Hence, we designed BACE1 inhibitor 
18 with an isophthalic scaffold at the P
2
 position [39]. However, compound 18 showed a 
low inhibitory activity (BACE1 inhibition 55% at 2 μM). Our next innovation involved the 
S
3
 sub-pocket located behind the active site of BACE1. A docking simulation study between 
Figure 5. (A) BACE1 inhibitors with an isophthalic scaffold reported by Elan Pharmaceuticals/Pharmacia and MSD and 
(B) design of isophthalic-type BACE1 inhibitors using a norstatine-type transition-state analog of KMI-574.
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inhibitor 18 and BACE1 revealed that the P
3
-phenyl group of inhibitor 18, which interacts 
with the S
3
 sub-pocket, adopts a folding structure against the P
2
-isophthalic scaffold. We envi-
sioned and designed an inhibitor that possessed a folding structure and synthesized inhibitor 
19. This compound featured a five-membered ring, oxazolidine, at the P
3
 position in order to 
fix the folding pose between the P
2
-phenyl group and P
3
-isophthalic scaffold. Our premise 
was that the oxazolidine ring fixes the direction of the phenyl ring at the P
3
 position, so the P
3
-
phenyl ring might be able to bind closely to the S
3
 sub-pocket of BACE1. Inhibitor 19 showed 
moderate inhibitory activity (BACE1 inhibition 85% at 2 μM, IC
50
 = 192 nM).
Next, we focused on a proton of the P
2
-isophthalic ring of inhibitor 19. We demonstrated van 
der Waals repulsion between the proton on the isophthalic ring at the P
2
 position and the 
five-membered ring at the P
3
 position in inhibitor 19 docked at the active site of BACE1. We 
focused on the steric-hindered interaction between the P
3
-phenyl group and a proton on the 
P
2
-isophthalic ring of a virtual inhibitor (Figure 6), which seemed to restrict its configuration. 
We calculated the steric energies in the respective conformers around the bond of the P
3
 amide 
and P
2
-isophthalic ring of the virtual inhibitors as shown in Figure 6. Using an approach based 
on a conformer of the docked inhibitor in BACE1 (the in silico conformational structure-based 
design) [39, 41], we adopted a pyridinedicarboxylic scaffold as a P
2
 moiety, which lacked a 
proton from the isophthalic ring. Whereas the conformer of the P
2
-isophthalic virtual inhibitor 
with the same dihedral angle to the conformer docked in BACE1 showed a high steric energy, 
the stable conformer of the virtual inhibitor with a P
2
-pyridinedicarboxylic scaffold showed 
the same dihedral angle to that docked in BACE1 because of the lack of a  proton on the pyri-
Figure 6. In-silico conformational structure-based design of BACE1 inhibitor possessing a pyridine scaffold at the P
2
 
position.
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dine’s amine. Inhibitor 20 with a pyridinedicarboxylic scaffold was designed and synthesized 
and showed improved inhibitory activity (BACE1 inhibition 93% at 2 μM, IC
50
 = 140 nM) com-
pared to 19 (Table 1). A docking simulation demonstrated that inhibitor 20 could adopt a sta-
ble folding structure having the same dihedral angle between the P
3
-amide and P
2
-isophthalic 
ring to the conformer docked in BACE1. Thus, we could design a potent BACE1 inhibitor 
(compound 20) using the computational approach based on the conformer docked in BACE1. 
However, 20 still showed a lower inhibitory activity than our peptidic inhibitors compared 
to lead compounds 13–15 (IC
50
 = 1.2–5.6 nM). There is room for further optimization of these 
inhibitors.
Compound X Y BACE1 inhibition % IC
50
 (nM)
at 2 μM at 0.2 μM
20 -H -H 93 63 140
21 -SO
2
CH
3
-H 96 73 96
22 -OCH
3
-H 91 53 151
23 -OEt -H 79 — —
24 -OPr -H 64 — —
25 -SCH
3
-H 95 66 89
26 -SCH(CH
3
)
2
-H 72 — —
27 -N
3
-H 95 68 79
28 -NH
2
-H 78 53 —
29 -N(CH
3
) SO
2
CH
3
-H 75 — —
30 -CH
3
-H 95 68 —
31 -Cl -H 98 87 22
32 -Br -H 99 88 15
33 -I -H 99 86 24
34 -Cl -F 99 91 13
35 -Br -F 99 93 9
36 -I -F 99 92 10
Table 1. BACE1 inhibitors with a pyridine scaffold.
Pyridine18
3.3. Design based on quantum chemical interaction and electron donor bioisostere
The first reported coordinate set of crystal structure of BACE1-inhibitor (OM99–2) complex 
is 1FKN by Gosh et al. [27–29]. The P2 moiety of the inhibitor interacts with the Arg235 side 
chain of BACE1 by hydrogen bonding in the crystal structure. We compared the publicly 
available X-ray crystal structures of BACE1-inhibitor complexes and discovered that most 
inhibitors did not interact with Arg235 by hydrogen bonding [41]. Surprisingly, the gua-
nidino group of BACE1-Arg235 in most crystal structures, except 1FKN, showed the similar 
“flopping over” feature of the P2 region of the inhibitors, and the nearest distances between 
the guanidino plane of Arg235 side chain and the P2 region of the inhibitor showed similar 
values of approximately 3 Å. The P2 moieties in many crystal structures that interact with the 
BACE1-Arg235 side chain are a methyl group, carbonyl oxygen atom, or aromatic ring. They 
appear to interact with the guanidine plane of Arg235 side chain by CH-π, O-π, or π-π stack-
ing interactions. This suggests that the π-orbital on the guanidino plane can interact with the 
P2 region of the inhibitors by a weak quantum force. The only exception was the interaction in the first reported X-ray crystal structure, 1FKN. Although the P2 moiety of OM99–2 in the crystal structure of 1FKN appeared to interact with the BACE1-Arg235 side chain via hydro-
gen bonding, the P2-moiety of OM00–3 that was structurally similar to OM99–2 interacted with the π-orbital on the guanidine plane of the BACE1-Arg235 side chain via O-π interac-
tion (PDB ID: 1M4H). Many early BACE1 inhibitors that possess a hydrogen bond receptor 
at the P2 position were designed using the 1FKN crystal structure. However, the hydrogen-
bonding interaction between most of the inhibitors and the BACE1-Arg235 side chain was 
not shown in their crystal structures. For instance, inhibitor 17 that was synthesized by the 
MSD researchers interacted with the BACE1-Arg235 side chain via a CH-π interaction (PDB 
ID: 2B8L) as shown in Figure 7A (PDB ID: 2B8L). It is likely that the researchers designed an 
inhibitor that possessed an N-methyl-N-methanesulfonyl group at the P2 position in anticipa-
tion of the hydrogen-bonding interaction between the sulfonyl oxygen atom and the BACE1-
Arg235 side chain. However, the N-methyl group of the inhibitor interacted with the π-orbital 
on the guanidine plane of the BACE1-Arg235 side chain at a distance of 2.8 Å. As described 
earlier, most of the BACE1 inhibitors, except OM99–2, in the crystal structure 1FKN, inter-
acted with the BACE1-Arg235 side chain by a weak quantum force such as stacking or σ-π 
interaction. The Arg235 side chain of the BACE1-OM99–2 complex (1FKN) assumed an excep-
tionally different pose to the other crystal structures. As many researchers have designed 
BACE1 inhibitors with a hydrogen bond receptor on the basis of the first reported crystal 
structure 1FKN, docking models using 1FKN will require further review. Furthermore, we 
found that the side chain of BACE1-Arg235 could move in concert with the inhibitor’s size. 
The guanidino planes of BACE1-Arg235 in the crystal structures of most BACE1 complexes 
showed similar distances from the P2 regions of the inhibitors regardless of their molecular 
size. This potentially posed a serious issue for a docking simulation for the drug discovery of 
BACE1 inhibitors. However, the BACE1-Arg235 side chain seems to have a restricted range 
of motion: the BACE1-Arg235 side chain slides sideways, not up and down, along the wall of 
the β-sheet structure that consists of four peptide strands behind the flap domain of BACE1. 
Therefore, the location of the BACE1-Arg235 side chain could be predicted by the inhibi-
tor’s size. We hypothesized that the role of the BACE1-Arg235 side chain is important for the 
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inhibitory mechanism of BACE1. The guanidine plane of Arg235 that can move in concert 
with the inhibitor’s size appears to push down on the P
2
 region of the inhibitor, which causes 
them to be affixed to the active site of BACE1 because of this “flop-over” mechanism by the 
BACE1-Arg235 side chain. Although a quantum chemical force, such as σ-π interaction, has 
a weaker binding energy than a hydrogen-bonding interaction, this “flop-over” mechanism 
permits a strong binding mode with the active site of BACE1.
In silico drug discovery using a docking simulation between a target biomolecule and drugs 
has provided important information. However, most docking simulation software involves 
mechanism/molecular dynamics (MM/MD) calculations based on classical Newtonian 
mechanics. Docking simulations using these calculations do not appear to estimate a weak 
quantum chemical interaction, such as stacking or σ-π interaction. The quantum chemical 
interactions that also involve other aromatic amino acids including phenylalanine (Phe), 
tyrosine (Tyr), and tryptophan (Trp) side chains seem to be approximately optimized using 
several descriptors based on classical mechanics in the docking simulation software that is 
based on MM/MD calculations. However, the software programs recognize arginine (Arg) 
as one of the charged amino acids, and the quantum chemical interactions involving an Arg 
Figure 7. Interaction of BACE1 inhibitors with the Arg235 side chain of BACE1. (A) MSD's inhibitor 17 (PDB ID: 2B8L) 
and (B) BMS's inhibitor (PDB ID: 4FSL).
Pyridine20
side chain are unlikely to yield a reasonable output. Quantum chemical interactions involv-
ing a π-orbital of a guanidino group are common in proteins and play an important role in 
molecular recognition by proteins. Crowley et al. surveyed cation-π interactions in protein 
interfaces using the Protein Data Bank and the Protein Quaternary Structure server [42]. They 
evaluated the cation-π interactions using a variant of the optimized potentials for liquid 
simulations (OPLS) force field and found that approximately half of the protein-protein 
complexes and one-third of the homodimers contained at least one intermolecular cation-π 
pair. This finding indicates the significance of these interactions in molecular recognition 
because the occurrence rate of cation-π pairs in protein-protein interfaces is higher than 
that in homodimer interfaces, which are similar to the protein interior. Among them, the 
interactions between an Arg and a Tyr were found to be the most abundant. Moreover, 53% 
of them involved planar π-π stacking by the quantum chemical interaction between the 
guanidine group of an Arg residue and the aromatic ring of a Tyr residue. Researchers at 
Bristol-Myers Squibb Research (BMS) reported a series of BACE1 inhibitors that can inter-
act with the BACE1-Arg235 side chain by a π-π stacking [43] as shown in Figure 7B (PDB 
ID: 4FSL). According to their structure–activity relationship study, the inhibitor possessing 
an electron-donating methoxy group on the p-position of phenyl ring that interacts with 
BACE1-Arg235 side chain can enhance BACE1-inhibitory activity. This finding indicated 
that an inhibitor possessing a P
2
-aromatic ring with a higher electron density could strongly 
bind to the electron-poor π-orbital on the guanidino plane of the BACE1-Arg235 side chain. 
We thought that inhibitors formulated on the basis of such a quantum chemical interaction 
could never be designed using a classical concept on the basis of Newtonian mechanics, such 
as MM/MD calculation. Hence, we proposed the new “electron-donor bioisostere,” concept, 
which involves quantum chemical interaction with an electron-poor π-orbital, such as the 
guanidine group of Arg235 [24].
We hypothesized that the quantum chemical interaction between an inhibitor and the side 
chain of BACE1-Arg235 plays a critical role in the inhibition mechanism. Therefore, we 
focused on the optimization around the P
2
 region. The finding of a structure–activity relation-
ship study focusing on the inhibitor’s P
2
 region is shown in Table 1 [39–41, 44]. Inhibitors 21, 
22, 25, 27, and 30 with hydrophobic and small-sized functional methanesulfonyl, methoxy, 
methylmercaptan, azide, and methyl groups on the P
2
-pyridine ring display a higher inhibi-
tory activity than inhibitors with a bulky or a hydrophilic group such as inhibitors 23, 24, 
26, 28, and 29. On the basis of the “electron-donor bioisostere” concept, we speculated that 
an electron-rich halogen atom could interact with the electron-poor guanidine π-orbital by 
Coulomb’s force. Using the ab initio molecular orbital approach, Imai et al. described the 
slightly stronger calculated Cl-π interaction energy than the CH-π interaction and reported 
that its energy was affected by π-electron density [45]. Hence, we designed inhibitors 31–33 
possessing a halogen atom on the P
2
-pyridine ring. Inhibitors 31–36 exhibited more potent 
inhibitory activities (IC
50
 values: 22, 15, and 24 nM, respectively). Next, inhibitors 34–36 pos-
sessing a fluorine atom on the p-position of P
3
-phenyl group exhibited the potent inhibitory 
activities (IC
50
 values: 13, 9, and 10 nM, respectively) [41]. Among them, inhibitor 35 (KMI-1303) 
exhibited the most potent inhibitory activity and is available from Wako Pure Chemical 
Industries (Japan) as a reagent for biological research.
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4. Conclusion
Pyridines are important in medicinal chemistry because of their properties, which include 
weak basicity, water solubility, in vivo/chemical stability, hydrogen bond-forming ability, and 
small molecular size. Pyridine moieties are incorporated in many drugs and pesticides. Water 
solubility is one role of pyridines. The replacement of a portion of drugs with a pyridine moiety 
can improve their water solubility for the development of practical drugs that are suitable for 
an orally administrated or an injectable formulation. This approach is also applicable to the 
prodrug strategy. The bioisostere is one of the important roles of pyridines in drug design. 
The abovementioned attributes of pyridines enable the application as a bioisostere of amines, 
amides, heterocyclic rings containing a/some nitrogen atoms, and the benzene ring. The replace-
ment of a part of lead compounds with pyridines is an important tool for the development of 
practical drugs. Moreover, the replacement of a portion of a drug molecule with pyridines 
might control the selectivity against subtypes of a target biomolecule, such as the histamine H
1
 
receptor antagonist, mepyramine. Recently, we reported a series of BACE1 inhibitors possess-
ing a pyridine scaffold. In this process, we observed an important and third role of pyridines in 
medicinal chemistry, other than the conventional role of pyridines. This chapter has discussed 
on this third role. The replacement of the isophthalic scaffold of inhibitors with a pyridinedicar-
boxylic scaffold enables the control of the conformation of inhibitors. We designed the potent 
BACE1 inhibitor KMI-1303 using the design approach based on a conformer of the docked 
inhibitor in the target molecule—the in silico conformational structure-based design.
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